Summary
The AI claims are about aspirin hypersensitivity/management and do not match or are not supported by the provided FDA-approved label excerpts for Aspirin and Extended-Release Dipyridamole Capsules (which primarily address stroke risk reduction, bleeding risk, and specific contraindications/precautions). No FDA label support is provided for most allergy-management assertions (e.g., epinephrine auto-injector use, emergency triage details, AERD/aspirin-exacerbated disease frameworks).
Category Scores
Accurate Statements
After suspected aspirin allergy, aspirin should be stopped.
Supported directionally by the label contraindication language indicating aspirin is contraindicated in patients with known allergy to NSAID products (4.2), but the label excerpt does not provide specific 'stop immediately after suspected allergy' instructions.
Unsupported Statements
If a person develops symptoms soon after taking aspirin—especially hives, swelling, wheezing, throat tightness, or trouble breathing—it may represent a serious allergic reaction.
The provided label excerpt does state aspirin may cause severe urticaria, angioedema or bronchospasm (4.2) but does not provide this symptom-timing triage framing for 'soon after taking aspirin' or 'trouble breathing/throat tightness' as a labeled interpretation.
Urgent medical care is recommended for suspected aspirin allergy, particularly for breathing problems, fainting, or rapidly worsening symptoms.
No corresponding emergency-care guidance is provided in the supplied label excerpts.
If the reaction includes breathing symptoms or severe swelling and the person has an epinephrine auto-injector prescribed, epinephrine should be used immediately.
No epinephrine auto-injector recommendation appears in the provided label excerpts.
If the reaction includes breathing symptoms or severe swelling and an epinephrine auto-injector is used, the person should go to the emergency department.
No emergency department guidance appears in the provided label excerpts.
A 'true allergy' to aspirin involves immediate reactions such as hives, swelling, wheezing, or anaphylaxis.
The label excerpt (4.2) mentions severe urticaria, angioedema or bronchospasm, but it does not define 'true allergy' or 'anaphylaxis' or specify immediacy.
AERD (aspirin-exacerbated respiratory disease) is a scenario where aspirin triggers or worsens asthma and sinus symptoms.
No AERD construct or definition is provided in the supplied label excerpts.
Aspirin-exacerbated skin disease is a scenario where aspirin worsens skin disease.
No aspirin-exacerbated skin disease framework is provided in the supplied label excerpts.
Management depends on which pattern (true allergy, AERD, or aspirin-exacerbated skin disease) the person has.
No management-by-pattern guidance is provided in the supplied label excerpts.
Clinicians typically ask about prior reactions and what symptoms occurred to determine which aspirin-related pattern applies.
No labeled clinical workflow or 'pattern' determination process is provided in the supplied label excerpts.
After a suspected aspirin allergy, aspirin should be avoided unless a clinician specifically clears it.
Label states contraindication in known allergy, but does not provide 'avoid unless cleared' language or a specific clinician-clearance workflow in the supplied excerpts.
After a suspected aspirin allergy, other medications in the same class (NSAIDs such as ibuprofen and naproxen) should often be avoided until evaluation because some people cross-react.
The supplied label excerpts do not discuss cross-reactivity with ibuprofen/naproxen or avoidance of other NSAIDs.
Many patients can use acetaminophen instead of aspirin.
No acetaminophen substitution guidance is provided in the supplied label excerpts.
The safe acetaminophen choice and dose should be confirmed with a clinician, especially if the person has asthma or a history of severe reactions.
No acetaminophen dosing/safety guidance or asthma-specific advice appears in the supplied label excerpts.
If the history strongly suggests aspirin sensitivity, a clinician may use allergy assessment.
No labeled recommendation about allergy assessment for aspirin sensitivity appears in the supplied excerpts.
If the history strongly suggests aspirin sensitivity, a clinician may perform supervised testing or an aspirin challenge in a controlled setting.
No labeled mention of supervised testing or aspirin challenge appears in the supplied excerpts.
For AERD, management may include evaluating asthma and nasal polyps.
No AERD-specific management content appears in the supplied label excerpts.
Selective COX-2 inhibitors may be tolerated by some people, but this requires clinician guidance.
No COX-2 inhibitor tolerability guidance appears in the supplied label excerpts.
If aspirin is needed for heart disease prevention or other reasons, doctors may consider specialist options such as desensitization in a monitored setting.
No desensitization or monitored specialist-option guidance appears in the supplied label excerpts.
For people who must take aspirin and have confirmed sensitivity, allergists can sometimes perform aspirin desensitization under close supervision.
No desensitization guidance appears in the supplied label excerpts.
Aspirin desensitization should not be tried at home because reactions can be severe.
No home-vs-clinic desensitization cautions appear in the supplied label excerpts.
Trouble breathing, wheezing, or repeated coughing after aspirin are indications for urgent/emergency care.
No urgent/emergency care triage language is provided in the supplied label excerpts.
Swelling of the lips, tongue, throat, or face is an indication for urgent/emergency care.
The label excerpt mentions angioedema (4.2) but provides no emergency triage criteria or anatomic list for action.
Dizziness, fainting, or low blood pressure symptoms are indications for urgent/emergency care.
No such symptoms or emergency-care guidance appears in the supplied label excerpts.
Widespread hives that spread quickly or rapidly worsening symptoms are indications for urgent/emergency care.
The label excerpt mentions severe urticaria (4.2) but does not provide emergency triage criteria like 'spread quickly' or 'rapidly worsening'.
Contradictions
Low
AI Statement
After a suspected aspirin allergy, aspirin should be stopped.
Label Reference
Label does not contradict stopping, but the claim is framed as general guidance after suspected allergy; the label excerpt provided only states contraindication in known allergy (4.2) and does not provide 'suspected' handling instructions. Therefore this is not marked as a direct contradiction.
Important Omissions
The AI response does not reflect the labeled indication of reducing stroke risk in patients with transient ischemia of the brain (TIA) or completed ischemic stroke due to thrombosis (1 INDICATIONS AND USAGE).
Importance:
Moderate
No labeled contraindication/precaution context is provided beyond general allergy advice; specifically, the label includes contraindication for asthma, rhinitis, and nasal polyps syndrome (4.2), and contraindications for children/teenagers with viral infections due to Reye syndrome (4.3), and warns about bleeding risk (5.1), renal failure (5.2), hepatic insufficiency (5.3), hypotension (5.5), and stress testing interruption (5.6).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The AI provides detailed emergency-treatment guidance (including epinephrine auto-injector use, emergency department instructions, and desensitization/COX-2 tolerability statements) that is not supported by the supplied FDA label excerpts. This mismatch could mislead users about appropriate labeled actions for suspected aspirin allergy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA label excerpts for Aspirin and Extended-Release Dipyridamole Capsules; the label excerpt mainly covers stroke-risk indication, contraindications (known hypersensitivity/NSAID allergy; asthma-rhinitis-nasal polyps; Reye syndrome in viral infections), and bleeding/other precautions rather than emergency triage or desensitization guidance.
Suggested Improvement
Limit allergy-related statements to what is supported by the provided label excerpts (e.g., contraindication in known NSAID allergy and asthma-rhinitis-nasal polyps; note aspirin may cause severe urticaria, angioedema, or bronchospasm). Remove unsupported specifics (epinephrine auto-injector use, emergency-department instructions, AERD/aspirin-exacerbated disease frameworks, acetaminophen substitution guidance, COX-2 tolerability, desensitization recommendations/testing procedures) unless additional on-label label text is provided.